Healthcare provider profile · identity verified

Daniel M Spatz, MD

Family Practice · LAURYS STATION, PA · NPI 1700872553

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Simvastatin	Simvastatin	528	143
Levothyroxine Sodium	Levothyroxine Sodium	400	112
Lisinopril	Lisinopril	361	108
Amlodipine Besylate	Amlodipine Besylate	355	106
Atorvastatin Calcium	Atorvastatin Calcium	298	91
Metformin Hcl	Metformin Hcl	295	96
Rosuvastatin Calcium	Rosuvastatin Calcium	293	92
Metoprolol Succinate	Metoprolol Succinate	196	55
Pantoprazole Sodium	Pantoprazole Sodium	183	64
Omeprazole	Omeprazole	171	54
Metoprolol Tartrate	Metoprolol Tartrate	169	49
Losartan Potassium	Losartan Potassium	139	44
Sertraline Hcl	Sertraline Hcl	125	42
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	124	36
Alprazolam	Alprazolam	122	36
Trazodone Hcl	Trazodone Hcl	121	43
Escitalopram Oxalate	Escitalopram Oxalate	119	41
Tamsulosin Hcl	Tamsulosin Hcl	118	39
Hydrochlorothiazide	Hydrochlorothiazide	116	38
Gabapentin	Gabapentin	115	42
Lorazepam	Lorazepam	115	27
Duloxetine Hcl	Duloxetine Hcl	105	33
Irbesartan	Irbesartan	100	28
Eliquis	Apixaban	96	22
Prednisone	Prednisone	87	50
Allopurinol	Allopurinol	84	25
Montelukast Sodium	Montelukast Sodium	78	22
Clopidogrel	Clopidogrel Bisulfate	77	25
Pravastatin Sodium	Pravastatin Sodium	75	21
Citalopram Hbr	Citalopram Hydrobromide	71	22
Atenolol	Atenolol	70	19
Fluoxetine Hcl	Fluoxetine Hcl	67	18
Furosemide	Furosemide	67	27
Azelastine Hcl	Azelastine Hcl	66	32
Glimepiride	Glimepiride	66	20
Synthroid	Levothyroxine Sodium	65	17
Jardiance	Empagliflozin	59	15
Fluticasone Propionate	Fluticasone Propionate	57	28
Azithromycin	Azithromycin	50	32
Albuterol Sulfate Hfa	Albuterol Sulfate	47	26
Donepezil Hcl	Donepezil Hcl	45	15
Meloxicam	Meloxicam	44	12
Famotidine	Famotidine	43	15
Valsartan	Valsartan	43	13
Esomeprazole Magnesium	Esomeprazole Magnesium	41	13
Ezetimibe	Ezetimibe	40	suppressed
Breo Ellipta	Fluticasone/Vilanterol	39	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	39	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	38	11
Paroxetine Hcl	Paroxetine Hcl	36	11
Potassium Chloride	Potassium Chloride	34	11
Venlafaxine Hcl Er	Venlafaxine Hcl	33	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	31	suppressed
Metformin Hcl Er	Metformin Hcl	31	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	31	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	30	suppressed
Finasteride	Finasteride	30	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	30	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	29	suppressed
Methocarbamol	Methocarbamol	29	suppressed
Trulicity	Dulaglutide	29	suppressed
Carvedilol	Carvedilol	28	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	28	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	27	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	27	suppressed
Valacyclovir	Valacyclovir Hcl	27	12
Buspirone Hcl	Buspirone Hcl	25	suppressed
Tradjenta	Linagliptin	25	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	24	suppressed
Ipratropium Bromide	Ipratropium Bromide	23	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	23	suppressed
Olanzapine	Olanzapine	23	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	22	suppressed
Januvia	Sitagliptin Phosphate	22	suppressed
Ezetimibe-Simvastatin	Ezetimibe/Simvastatin	21	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	21	suppressed
Tizanidine Hcl	Tizanidine Hcl	21	suppressed
Mirtazapine	Mirtazapine	20	suppressed
Tramadol Hcl	Tramadol Hcl	20	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	19	suppressed
Ramipril	Ramipril	19	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	19	suppressed
Warfarin Sodium	Warfarin Sodium	18	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	17	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	17	suppressed
Ozempic	Semaglutide	17	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	16	15
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	16	suppressed
Pregabalin	Pregabalin	16	suppressed
Colchicine	Colchicine	15	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	15	11
Doxazosin Mesylate	Doxazosin Mesylate	15	suppressed
Lansoprazole	Lansoprazole	15	suppressed
Vascepa	Icosapent Ethyl	15	suppressed
Benazepril Hcl	Benazepril Hcl	14	suppressed
Meclizine Hcl	Meclizine Hcl	14	suppressed
Mometasone Furoate	Mometasone Furoate	14	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	14	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	14	suppressed
Rizatriptan	Rizatriptan Benzoate	14	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	14	suppressed
Bupropion Xl	Bupropion Hcl	13	suppressed
Celecoxib	Celecoxib	13	suppressed
Clindamycin Hcl	Clindamycin Hcl	13	11
Linzess	Linaclotide	13	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	12	suppressed
Enalapril Maleate	Enalapril Maleate	12	suppressed
Lovastatin	Lovastatin	12	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	12	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	12	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	12	suppressed
Amoxicillin	Amoxicillin	11	suppressed
Cephalexin	Cephalexin	11	suppressed
Digoxin	Digoxin	11	suppressed
Glyburide	Glyburide	11	suppressed
Prazosin Hcl	Prazosin Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error